Get Hold Of: This Includes Just About Everything Regarding Onalespib

At present, the only evidence-based remedy for glaucoma is to lower IOP.3�C7 The practical goal of treatment is to reduce IOP by 20%�C30% from baseline.3�C5,8�C12 The association between a reduction in IOP and the progression of visual field defects has been fully studied for POAG. Relatively high IOP has also been recognized to be evaluated as a major risk factor for the progression of visual field defects in NTG.4,5,13,14 NTG is, therefore, treated in the same way as POAG, although there have been few large-scale studies that had as their main focus on IOP and the progression of visual field defects. It was, therefore, decided to analyze the relationship between IOP and the progression of visual field defects in Japanese POAG and NTG patients. Materials and methods Study design This was a multicenter, retrospective, and observational study. Subjects The study subjects were patients who underwent treatment for POAG or NTG between 1999 and 2011 at Okayama University, Minami-Matsuyama Hospital, Kagurazaka Minamino Eye Clinic, Ueno Eye Clinic, Suzumura Eye Clinic, Yoshikawa Eye Clinic, and Nihonmatsu Eye Hospital who met the enrolment conditions and did not fulfill the exclusion criteria described below. The inclusion criteria for this study were: 1) age ��20 years; 2) having obvious glaucomatous visual field defects in accordance with Anderson��s criteria;15 3) having visual field testing with a Humphrey field analyzer (Zeiss-Humphrey Systems, San Leandro, CA, USA) at least a total of ten times, in principle every 6 months without alteration in strategy (Swedish interactive thresholding algorithm standard) or program (C30-2); 4) capable of undergoing assessment of the mean deviation (MD) slope by using HfaFiles (Beeline, Tokyo, Japan); 5) baseline IOP was measured at least three times applying a Goldmann applanation tonometer before undergoing treatment; and 6) IOP was measured regularly during the follow-up period. The exclusion criteria were as Cisplatin follows: 1) MD